Adolor at buy by Merrill

Merrill Lynch analyst David Munno rated Adolor Corp. at a buy on the belief there is a high probability of approval for Entereg in post-operative ileus by its Nov. 9 PDUFA date, making the stock worth about $18. If additional studies are required or Entereg is not approved, the stock could trade at around $10 to $11, according to the analyst. Shares of the Exton, Pa.-based biopharmaceutical company were down 10 cents, or 0.73%, at $13.61. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.